{
    "id": 23842,
    "cites": 26,
    "cited_by": 0,
    "reference": [
        "Acemoglu D, Linn J. Market size in innovation: theory and evidence from the pharmaceutical industry. The Quarterly Journal of Economics. August 2004:41.",
        "Bach P. Could High Drug Prices Be Bad For Innovation? Forbes 2014.",
        "Bach PB, Pearson SD. Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs. JAMA. Dec 15 2015;314(23):2503-2504.",
        "Bach PB. Limits on Medicare&apos;s ability to control rising spending on cancer drugs. The New England Journal of Medicine. Feb 5 2009;360(6):626-633.",
        "Bennette CS, Richards C, Sullivan SD, Ramsey SD. Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure. Health affairs. May 1 2016;35(5):805-812.",
        "Blume-Kohout ME, Sood N. Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development. Journal of Public Economics. Jan 2013;97:327-336.",
        "Bowman J, Rousseau A, Silk D, Harrison C. Access to cancer drugs in Medicare Part D: Formulary placement and beneficiary cost sharing in 2006. Health Affairs 2006; 25(5): 1240-1248.",
        "CMS proposes to test new Medicare Part B prescription drug models to improve quality of care and deliver better value for Medicare beneficiaries. 2016; https://http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016Fact -sheets-items/2016-03-08.html. Accessed April 6, 2016.",
        "DiMasi JA, Faden LB. Competitiveness in follow-on drug R&D: a race or imitation? Nature Reviews Drug Discovery 2011; 10: 23-27.",
        "Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA. Jan 22-29 2014;311(4):368-377.",
        "Friedman JN. The Incidence of the Medicare Prescription Drug Benefit: Using Asset Prices to Assess its Impact on Drug Makers. Harvard University; 2009. Job Market Paper.",
        "Gold LS, Buist DS, Loggers ET, et al. Advanced diagnostic breast cancer imaging: variation and patterns of care in Washington state. J Oncol Pract. Sep 2013;9(5):e194-202. HHS Pharmaceutical Forum: Innovation, Access, Affordability and Better Health.",
        "Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the Market for Anti-cancer Drugs. Journal of Economic Perspectives. 2015;29(1):139-162.",
        "Institute of Medicine. Delivering Affordable Cancer Care in the 21st Century: Workshop Summary. Washington, DC: The National Academies Press, 2013. doi:10.17226/18273.",
        "Institute of Medicine. Ensuring Patient Access to Affordable Cancer Drugs: Workshop Summary. Washington, DC: The National Academies Press, 2014. doi:10.17226/18956.",
        "Kim C, Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Internal Medicine. Dec 2015;175(12):1992-1994.",
        "Lakdawalla D, Sood N, Gu Q. Pharmaceutical advertising and Medicare Part D. Journal of Health Economics. Dec 2013;32(6):1356-1367. Loftus P. New Push Ties Cost of Drugs to How Well They Work. Wall Street Journal2015.",
        "Mailankody S, Prasad V. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. JAMA. May 5 2016.",
        "Martell RE, Sermer D, Getz K, Kaitin KI. Oncology drug development and approval of systemic anti-cancer therapy by the U.S. Food and Drug Administration. The Oncologist. 2013;18(1):104-111.",
        "Morgan S, Kennedy J. Prescription drug accessibility and affordability in the United States and abroad. Commonwealth Fund Pub 1408, 2010; vol. 49.",
        "http://www.commonwealthfund.org/~/media/Files/Publications/Issue%20Brief/2010/J un/1408_Morgan_Prescription_drug_accessibility_US_intl_ib.pdf. Accessed August 2017.",
        "Pollack A. Sanofi Halves Price of Cancer Drug Zaltrap After Sloan-Kettering Rejection. New York Times. November 8, 2012.",
        "Prasad V, Jena AB. Prespecified falsification end points: can they validate true observational associations? JAMA Jan 16 2013;309(3):241-242. Prasad V, Kim C, Burotto M, Vandross A. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.",
        "Ramsey SD, Lyman GH, Bangs R. Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs: Pick Your Poison. JAMA Oncology. Apr 1 2016;2(4):425-426.",
        "Scherer FM. The link between gross profitability and pharmaceutical R&D spending. Health Affairs. Sep-Oct 2001; 20(5):216-220.",
        "Yeung, K., Basu, A., Hansen, R. N., Watkins, J. B., & Sullivan, S. D. (2016). Impact of a Valuebased Formulary on Medication Utilization, Health Services Utilization, and Expenditures. Medical Care. DOI: 10.1097/MLR.0000000000000630"
    ]
}